600 related articles for article (PubMed ID: 17640745)
21. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
Violin M; Forbici F; Cozzi-Lepri A; Velleca R; Bertoli A; Riva C; Giannella S; Manconi PE; Lazzarin A; Pasquinucci S; Tacconi L; Carnevale G; Mazzotta F; Bonazzi L; Montroni M; Chirianni A; Capobianchi M; Ippolito G; Moroni M; Perno CF; D'Arminio-Monforte A;
J Biol Regul Homeost Agents; 2002; 16(1):37-43. PubMed ID: 12003172
[TBL] [Abstract][Full Text] [Related]
22. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
23. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
Gatanaga H; Hachiya A; Kimura S; Oka S
Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
[TBL] [Abstract][Full Text] [Related]
25. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
26. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
27. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
28. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
29. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
[TBL] [Abstract][Full Text] [Related]
30. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
31. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
Paintsil E; Margolis A; Collins JA; Alexander L
J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
[TBL] [Abstract][Full Text] [Related]
32. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
33. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
[TBL] [Abstract][Full Text] [Related]
34. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
[TBL] [Abstract][Full Text] [Related]
35. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
36. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ; Chappey C; Parkin NT; Miller MD
Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
[TBL] [Abstract][Full Text] [Related]
38. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
40. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
